BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the appointment of John J. Crowley as Chief Financial Officer. In this position, Mr. Crowley will lead Fusion’s finance function, reporting to John Valliant, Ph.D., Chief Executive Officer of Fusion Pharmaceuticals.
“I am pleased to welcome John to the Fusion team at this exciting time in the Company’s evolution, as we advance our lead program, FPI-1434, in the clinic,” said John Valliant, Ph.D., CEO of Fusion. “John’s proven leadership and experience in building global finance organizations to support aggressive growth will be critical, as Fusion progresses its targeted alpha-particle radiotherapeutic platform across multiple indications in oncology.”
Mr. Crowley brings to Fusion over 20 years of global biotechnology financial and operational experience. Most recently, he served as Executive Vice President and Chief Financial Officer at Merus, Inc., where he led the finance and investor relations functions and was instrumental in the build-out of the company’s U.S. and global operations. Prior to joining Merus, Mr. Crowley served as Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories, Inc. Previously, he served as Vice President, Corporate Controller and Chief Accounting Officer of Ironwood Pharmaceuticals, Inc. and held senior corporate finance positions at Vertex Pharmaceuticals, Inc. and Sunovion Pharmaceuticals, Inc. Mr. Crowley is a Certified Public Accountant and graduated Summa Cum Laude from Babson College with B.S. degrees in both Economics and Accountancy.
“I am honored to join such a talented leadership team as it pioneers a unique and powerful radiotherapeutic platform with a vision of developing innovative medicines for the treatment of cancer,” said John J. Crowley. “We have a unique opportunity to improve the lives of patients, and I look forward to working with the team to advance these scientific breakthroughs and help contribute to our continued success.”
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules, via its proprietary Fast-Clear™ Technology Platform, to create highly effective therapeutics. In addition to its lead program, FPI-1434, which had its first patient dosed in a Phase I trial in February 2019, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships. For more information, please visit Fusion Pharmaceuticals or contact info@fusionpharma.com.
